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It has been known for some time that some oncologic
drugs can cause heart damage. The term
‘cardiotoxicity’ just refers to the presence of a cardiac
event during therapy or at least related to therapy.
As a matter of fact, cardiovascular complications
may be due to cancer itself and to cancer treatment,
ranging from hypertension to asymptomatic left ven-
tricular dysfunction, arrhythmias, myocardial ischemia,
peripheral artery disease, thromboembolism, heart fail-
ure (HF) and even sudden cardiac death. Therefore,
detecting and managing cardiac effects of cancer
therapies have become an important issue in
oncology.
The remarkable impact of cardiovascular complica-
tions, especially in patients receiving cardio-toxic
therapies, also led authoritative cardiologic society
(ACC/AHA/ASE) to consider these as class-A patients
for HF (at risk) and to develop a class I recommenda-
tion for their regular monitoring [1]. More recently,
dedicated guidelines and position papers considered a
wide spectrum of cardiovascular toxicity [2,3].
As a result, cardio-oncology is a new multidisciplin-
ary approach that, due to the best knowledge of the
cardio-toxic effects of many antineoplastic therapies,
focuses on screening, monitoring, preventing and
treating cardiovascular disease in cancer patients. It
may identify patients with pre-existing cardiac abnor-
malities that are especially susceptible to therapy-
related cardiotoxicity, and facilitate early therapeutic
measures providing optimal care to patients [4].
So far, despite the sensitivity to this topic and the
extensive literature, cardio-oncology has been
approached focusing primarily on individual drugs
with a high risk of cardiovascular toxicity, and in the
context of hematological diseases, the focus has been
on lymphoma treatment, especially monitoring the left
ventricular ejection fraction (LVEF) in anthracycline-
based therapy. In addition, even if many recommenda-
tions are available, in the real life few cancer patients
are subjected to appropriate monitoring programs and
do not always receive specific therapy according to
ACC/AHA guidelines [5].
Multiple myeloma (MM) is a plasma cell disorder
that accounts for around 10% of all hematological
malignancies, the second following non-Hodgkin's lym-
phomas. This neoplasia is often associated with high
prevalence of cardiovascular complications resulting
from several factors, either unrelated and related to
the disease. Among those unrelated to the cancer,
generally previous to diagnosis, there are diabetes,
hypertension, dyslipidemia, smoking habit and mostly,
for the greater incidence in elderly patients, older age.
Beyond that, MM may lead to several cardiac effects,
through disease-related and treatment-related factors.
Underlying cardiac amyloidosis, often not detected at
diagnosis, together with hyperviscosity, arteriovenous
shunting, high-output failure, anemia and renal dys-
function, are cardiac risk factors related to multiple
myeloma [6,7]. Many are also the therapy-related risk
factors. For example, the use of corticosteroids, espe-
cially for a long time, might cause arrhythmias, hyper-
glycemia, hypertension, diabetes and obesity.
Alkylating agents may lead to myopericarditis, cardio-
myopathy, thrombosis and reduced left ventricular
ejection fraction. Immunomodulatory drugs can induce
arrhythmias and myocardial ischemia. The therapy
with proteasome inhibitors may result in congestive
heart failure (CHF), myocardial ischemia, arrhythmias,
atrioventricular block and hypertension [8].
Furthermore, the transplant patients are at risk of
developing HF, cardiomyopathy, myocardial ischemia
and rhythm disorders [9]. Finally, the risk of cardiac
effects associated with supportive therapies should
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also be taken into account. For example, some antibi-
otics (e.g. macrolides, quinolones) or antifungal agents
(e.g. fluconazole, pentamidine) can cause the QT
prolongation.
In our opinion, it is time to create a new chapter of
cardio-oncology which is entirely devoted to multiple
myeloma and adopts a disease-oriented approach
rather than a therapy-oriented one.
Indeed, multiple myeloma is a complex and hetero-
geneous disease in which, as stated above, the CV risk
is inherent in the pathophysiology. Therefore, a differ-
ent management is necessary, as it is in the case of
thromboprophylaxis for which Khorana score does not
apply, but a specific approach is recommended
according to the individual risk factors and the type of
therapy [10].
In addition, it should be noted that multiple mye-
loma remains an incurable disease, with frequent
relapses in the natural history. The development of
new effective drugs has improved the clinical out-
comes and increased life expectancy, but on the other
hand, many patients receive numerous treatment lines.
All this results in a greater risk of significant cumula-
tive toxicity, especially in people younger than 65
years old who represent approximately 37% of all
patients with MM and are also candidates for bone
marrow transplant.
For this reason, we are proposing a comprehensive
cardiologic evaluation, already at baseline. Firstly, an
accurate assessment of cardiovascular risk factors and
comorbidities should be performed at diagnosis, along
with potential corrective actions (blood pressure con-
trol, lipid level reduction, smoking cessation, etc.). This
needs to be combined to a clinical, ECG and imaging
evaluation. With respect to imaging techniques, base-
line echocardiography is crucial not only for LVEF evalu-
ation, but also for the assessment of any alteration,
including findings of amyloidosis (increased left and
right ventricular wall thickness, diastolic dysfunction
with a restrictive pattern, pericardial effusion, etc.). In
addition, serum cardiac biomarkers, B-type natriuretic
peptide (BNP) and troponins, are likely to serve as earlier
markers of cardiac toxicity, when carefully interpreted.
This assessment should also be carried out at the end of
treatment and repeated for any subsequent therapy
line. To this end, a multidisciplinary approach involving
cardiology plays a key role, being critical for the optimal
management of the patient.
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